Poseida and Astellas Join Forces to Develop Innovative CAR-T Cancer Therapies

Poseida Therapeutics and Xyphos Biosciences enter a research collaboration to develop novel convertible CAR programs targeting solid tumors. Poseida will receive $50 million upfront and up to $550 million in milestones, plus royalties, for the development of two convertible CAR product candidates.

author-image
Hadeel Hashem
Updated On
New Update
Poseida and Astellas Join Forces to Develop Innovative CAR-T Cancer Therapies

Poseida and Astellas Join Forces to Develop Innovative CAR-T Cancer Therapies

Poseida Therapeutics Inc. and Xyphos Biosciences Inc., a wholly-owned subsidiary of Astellas Pharma Inc., have entered into a groundbreaking research collaboration and license agreement to develop novel convertible CAR programs. The partnership aims to combine Poseida's proprietary allogeneic CAR-T platform with Xyphos' innovative ACCEL technology to create two convertible CAR product candidates targeting solid tumors.

Why this matters: This collaboration has the potential to transform the treatment of solid tumors, which are notoriously difficult to treat with current cancer therapies. The development of innovative CAR-T cell therapies could lead to improved patient outcomes and increased hope for those battling these aggressive cancers. The development of innovative CAR-T cell therapies could lead to improved patient outcomes and increased hope for those battling these aggressive cancers.

Under the terms of the agreement, Poseida will receive an upfront payment of $50 million and is eligible for up to $550 million in potential development and sales milestones, plus contingency payments. Additionally, Poseida will be entitled to receive up to low double-digit tiered royalties as a percentage of net sales. Xyphos will cover the costs incurred by Poseida during theresearch phaseand will be responsible for the development and eventual commercialization of the products resulting from the collaboration.

Kristin Yarema, Ph.D., President and CEO of Poseida, expressed her enthusiasm for the collaboration, stating, "We are excited to expand our relationship with Astellas, where we share a vision that innovative off-the-shelf cell therapies can address significant unmet needs of patients with solid tumor malignancies. "This sentiment was echoed by Adam Pearson, Chief Strategy Officer of Astellas, who added, "By combining the ACCEL platform with Poseida's advanced and sophisticated genetic editing platforms, we believe the collaboration will bring synergies between the two companies breakthrough research and will lead to the expansion of Astellas' portfolio and the delivery of innovative CAR-T cell therapies to cancer patients."

This collaboration builds upon a strategic investment by Astellas in Poseida in August 2023 to support Poseida's commitment to redefining cancer cell therapy. Poseida is advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases, with a pipeline including allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors.

Xyphos Biosciences, launched in 2017 and acquired by Astellas Pharma in December 2019, utilizes a novel and proprietary ACCEL technology platform that uses convertibleCAR technology in combination with proprietary MicAbodies to target tumor cells. The ACCEL platform employs a modified form of the natural human NKG2D receptor, enabling immune surveillance. The engineered NKG2D receptor allows the convertible CAR construct to be controlled and activated by tumor-specific activator bispecific antibodies.

The collaboration between Poseida Therapeutics and Xyphos Biosciences represents a significant milestone in the development of innovative CAR-T cell therapies for solid tumors. By leveraging their respective technologies and expertise, the companies aim to overcome the challenges associated with treating solid tumors and provide new hope for patients battling these difficult-to-treat cancers.

The field of immuno-oncology continues to evolve, and partnerships like this one between Poseida and Xyphos showcase the potential for collaborative efforts to accelerate the development of groundbreaking therapies. With the financial support and shared vision of both companies, the future looks promising for patients in need of more effective and targeted cancer treatments.

The companies will collaborate to develop novel allogeneic cell therapies in oncology, combining Poseida's proprietary allogeneic CAR-T platform with Xyphos' innovative ACCEL technology to create two convertible CAR product candidates targeting solid tumors.

This is the second research collaboration between Astellas and Poseida, building upon a strategic investment by Astellas in Poseida in August 2023 to support Poseida's commitment to redefining cancer cell therapy.

Key Takeaways

  • Poseida Therapeutics and Xyphos Biosciences partner to develop novel convertible CAR programs for solid tumors.
  • The collaboration aims to combine Poseida's allogeneic CAR-T platform with Xyphos' ACCEL technology.
  • Poseida is to receive $50M upfront, up to $550M in milestones, and tiered royalties.
  • Partnership targets improved patient outcomes for solid tumors, a notoriously difficult-to-treat cancer type.
  • This is the second research collaboration between Astellas and Poseida, following a strategic investment in 2023.